Integrated Diagnostics Holdings (LSE:IDHC) Net Margin %: 21.08% (As of Mar. 2026) — Near Median


LSE:IDHC Integrated Diagnostics Holdings PLC LSE:IDHC
58 GF Score
Price $0.50
GF Value $0.57
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Integrated Diagnostics Holdings Net Margin %?

Integrated Diagnostics Holdings LSE:IDHC +0.40% 58 Net Margin % is 21.08% as of Mar. 2026, which is 6% below its 10-year median of 22.31. GuruFocus rates LSE:IDHC with a GF Score™ of 58/100 and a GF Value™ of $0.57 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Integrated Diagnostics Holdings ranks better than 93.63% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Integrated Diagnostics Holdings's Net Income for the three months ended in Mar. 2026 was $9.20 Mil. Integrated Diagnostics Holdings's Revenue for the three months ended in Mar. 2026 was $43.63 Mil. Therefore, Integrated Diagnostics Holdings's net margin for the quarter that ended in Mar. 2026 was 21.08%.

The historical rank and industry rank for Integrated Diagnostics Holdings's Net Margin % or its related term are showing as below:

LSE:IDHC' s Net Margin % Range Over the Past 10 Years
Min: 12.38   Med: 22.31   Max: 27.04
Current: 21.08


LSE:IDHC's Net Margin % is ranked better than
93.63% of 204 companies
in the Medical Diagnostics & Research industry
Industry Median: -2.405 vs LSE:IDHC: 21.08

Integrated Diagnostics Holdings  (LSE:IDHC) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Integrated Diagnostics Holdings Net Margin % Related Terms


Integrated Diagnostics Holdings Net Margin % Historical Data

* Premium members only.

The historical data trend for Integrated Diagnostics Holdings's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Integrated Diagnostics Holdings Net Margin % Chart

Integrated Diagnostics Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.04 15.01 12.38 18.84 16.07

Integrated Diagnostics Holdings Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.51 0.00 15.48 0.00 21.08

LSE:IDHC vs TMO, DHR, IDXX: Net Margin % Comparison

For the Diagnostics & Research subindustry, Integrated Diagnostics Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Integrated Diagnostics Holdings Net Margin % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Integrated Diagnostics Holdings's Net Margin % distribution charts can be found below:

* The bar in red indicates where Integrated Diagnostics Holdings's Net Margin % falls into.


LSE:IDHC
58GF Score
Integrated Diagnostics Holdings PLC LSE:IDHC
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Integrated Diagnostics Holdings Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Integrated Diagnostics Holdings's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=26.565/165.328
=16.07 %

Integrated Diagnostics Holdings's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=9.197/43.629
=21.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 21.08% mean?
Integrated Diagnostics Holdings (LSE:IDHC) has a Net Margin % of 21.08% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Integrated Diagnostics Holdings and its competitors. This is near median its historical median of 22.31. Over the past decade, Integrated Diagnostics Holdings' Net Margin % has ranged from 12.38 to 27.04. According to the industry distribution chart, Integrated Diagnostics Holdings ranks #13 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 6.4%.
Is Integrated Diagnostics Holdings' Net Margin % too high?
Integrated Diagnostics Holdings' current Net Margin % of 21.08% is near median its 10-year median of 22.31. Over the past 10 years, this metric has ranged from a low of 12.38 to a high of 27.04. Based on the distribution chart, Integrated Diagnostics Holdings ranks #13 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Integrated Diagnostics Holdings has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integrated Diagnostics Holdings' Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integrated Diagnostics Holdings ranks #13 out of 204 companies for Net Margin %. This places Integrated Diagnostics Holdings in the top 6% of its industry — outperforming the majority of peers. Historically, Integrated Diagnostics Holdings' own Net Margin % has ranged from 12.38 to 27.04 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Integrated Diagnostics Holdings and its competitors. Integrated Diagnostics Holdings's current Net Margin % is 21.08%, which is near median its own 10-year median of 22.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings (LSE:IDHC) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.57, compared to a current price of $0.50 — trading 11.9% below its estimated fair value. The current Net Margin % is 21.08%, which is near median its 10-year median of 22.31. Integrated Diagnostics Holdings' overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Integrated Diagnostics Holdings (LSE:IDHC), the current Net Margin % is 21.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Integrated Diagnostics Holdings (LSE:IDHC) Overvalued in 2026?

Based on GuruFocus' analysis, Integrated Diagnostics Holdings stock appears to be undervalued. The current stock price of $0.50 is trading 11.9% below its estimated GF Value™ of $0.57. GuruFocus considers Integrated Diagnostics Holdings to be Modestly Undervalued.

Key valuation signals for LSE:IDHC:

  • Net Margin %: 21.08% (near median its 10-year median of 22.31)
  • GF Value™: $0.57 vs. price of $0.50 (11.9% below fair value)
  • GF Score™: 58/100 with 6 warning signs

No single metric tells the full story. See the LSE:IDHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Integrated Diagnostics Holdings Business Description

Address 12 Castle Street, St Helier, JEY, JE2 3RT
Integrated Diagnostics Holdings PLC is active in the healthcare sector. It is a fully integrated diagnostics service provider, operating through brands such as Al Borg and Al Mokhtabar in Egypt, as well as Biolab in Jordan and Ultralab and Al Mokhtabar Sudan in Sudan, Echo-Lab in Nigeria, and Biolab KSA in Saudi Arabia. The company specializes in diagnostic tests, ranging from basic tests, such as glucose testing for diabetes, to molecular tests for hepatitis and specialized DNA tests. The company operates in two segments: the Contract Segment, which generates key revenue, and the Walk-in Segment. It derives a majority of its revenue from services offered in Egypt.
58GF Score

Get the complete analysis for LSE:IDHC

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.50
Price
$0.57
GF Value